🇺🇸 FDA
Pipeline program

C1 inhibitor (human) [C1 INH]

0624-400

Approved mab completed

Quick answer

C1 inhibitor (human) [C1 INH] for Hereditary Angioedema is a Approved program (mab) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Hereditary Angioedema
Phase
Approved
Modality
mab
Status
completed

Clinical trials